Anavex Life Sciences Corp (AVXL)

[Hoskuld]

Is it more interesting? Is it disappointing?

Well, no it isn't more interesting and no it isn't disappointing. You know what is interesting? Answer: that all primary and secondary endpoints have been hit for every 2-73 trial. That is pretty interesting. You know what isn't interesting? Answer: making up scenarios where the company might be lying. It is kind of boring to keep inventing your own side game where if you imagine certain things to be true then reality is unreal.